Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $422,148.36 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $253.07 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The stock has a 50-day moving average price of $271.48 and a 200 day moving average price of $240.29. The stock has a market capitalization of $32.64 billion, a P/E ratio of -96.59 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the prior year, the company earned $1.15 EPS. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Plato Investment Management Ltd grew its position in shares of Alnylam Pharmaceuticals by 2,666.3% during the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after purchasing an additional 4,346 shares in the last quarter. Diversified Trust Co bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $1,210,000. Los Angeles Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after buying an additional 135,829 shares during the last quarter. Breakwater Capital Group bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $249,000. Finally, Sanctuary Advisors LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $578,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the topic of a number of research analyst reports. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Scotiabank upped their price target on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. HC Wainwright reiterated a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Chardan Capital reiterated a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, TD Cowen upped their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.